Deutsche Bank AG Upgrades Zimmer Biomet Holdings, Inc. (ZBH) to “Buy”

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) was upgraded by investment analysts at Deutsche Bank AG from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The brokerage currently has a $128.00 target price on the medical equipment provider’s stock. Deutsche Bank AG’s price target indicates a potential upside of 15.23% from the company’s current price.

A number of other equities analysts also recently issued reports on the company. Morgan Stanley upped their price target on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 17th. Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BidaskClub downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Canaccord Genuity downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and decreased their price objective for the company from $141.00 to $135.00 in a report on Friday, July 28th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $135.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings has a consensus rating of “Hold” and an average price target of $133.71.

Shares of Zimmer Biomet Holdings (NYSE ZBH) traded down $1.13 on Tuesday, reaching $111.08. The company had a trading volume of 1,149,900 shares, compared to its average volume of 1,364,914. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. The firm has a market capitalization of $22,719.51, a P/E ratio of 13.90, a price-to-earnings-growth ratio of 1.74 and a beta of 1.17. Zimmer Biomet Holdings has a 52-week low of $98.20 and a 52-week high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period last year, the company earned $1.79 earnings per share. equities research analysts predict that Zimmer Biomet Holdings will post 8.03 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.truebluetribune.com/2017/11/16/deutsche-bank-ag-upgrades-zimmer-biomet-holdings-inc-zbh-to-buy.html.

A number of large investors have recently added to or reduced their stakes in ZBH. Bronfman E.L. Rothschild L.P. raised its position in Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after acquiring an additional 167 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after acquiring an additional 33 shares in the last quarter. Bank of Nova Scotia Trust Co. purchased a new position in Zimmer Biomet Holdings in the third quarter worth $112,000. FNY Managed Accounts LLC purchased a new position in Zimmer Biomet Holdings in the third quarter worth $117,000. Finally, BB&T Investment Services Inc. purchased a new position in Zimmer Biomet Holdings in the second quarter worth $144,000. Hedge funds and other institutional investors own 85.44% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply